Financial Performance - The company reported a total other income of RMB 28.1 million for the first half of 2025, representing a year-on-year decrease of 60.4% [1] - Research and development expenses amounted to RMB 117 million, down 7.3% year-on-year [1] - The net loss for the period was approximately RMB 149 million, a reduction of 47.5% compared to the previous year [1] - Loss attributable to shareholders was about RMB 148 million, reflecting a decrease of 47.22% year-on-year [1] - The reduction in losses was primarily due to a decrease in other losses related to fair value changes of equity investments by RMB 115.5 million, a decrease in impairment losses under expected credit loss model by RMB 33 million, and a reduction in operating expenses [1] Strategic Developments - The company achieved a significant milestone by granting an external license for soralimixin (BRII-693), a new antibiotic for treating severe MDR/XDR Gram-negative bacterial infections [2] - In July 2025, the company announced a collaboration with Health元 Group to grant rights for research, development, and commercialization of soralimixin (BRII-693) in the Greater China region [2] - This partnership allows the company to focus its internal resources on core HBV projects while advancing the regional development and commercialization of soralimixin (BRII-693) [2] - The collaboration is expected to accelerate access to urgently needed anti-infection treatments in Greater China, and clinical data generated during the development process may support further development of soralimixin (BRII-693) in other regions [2]
腾盛博药-B公布中期业绩 公司拥有人应占亏损约1.48亿元 同比减少47.22%